In a filing, Akero Therapeutics Inc revealed its Chief Scientific Officer Rolph Timothy unloaded Company’s shares for reported $0.26 million on Apr 24 ’25. In the deal valued at $41.03 per share,6,250 shares were sold. As a result of this transaction, Rolph Timothy now holds 169,721 shares worth roughly $7.3 million.
Then, Yale Catriona sold 9,073 shares, generating $343,962 in total proceeds. Upon selling the shares at $37.91, the Chief Development Officer now owns 95,034 shares.
Before that, Cheng Andrew sold 30,000 shares. Akero Therapeutics Inc shares valued at $1,056,780 were divested by the President and CEO at a price of $35.23 per share. As a result of the transaction, Cheng Andrew now holds 624,324 shares, worth roughly $26.87 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Tuesday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock jump 2.06% to $43.04. Over the last five days, the stock has gained 11.79%. Akero Therapeutics Inc shares have risen nearly 54.71% since the year began. Nevertheless, the stocks have risen 127.36% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $17.86 was recorded on 01/14/25. SMA at 50 days reached $42.75, while 200 days put it at $33.68.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 41.77, which if violated will result in even more drops to 40.50. On the upside, there is a resistance level at 43.88. A further resistance level may holdings at 44.72. The Relative Strength Index (RSI) on the 14-day chart is 59.23, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.39, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 3.52%. Stochastics %K at 95.94% indicates the stock is a selling.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-04-15, growing by 1.11 million shares to a total of 6.31 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 5.2 million shares. There was a rise of 17.52%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
